Clinical Trial Update: CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating ceftolozane-tazobactam for empiric anti-bacterial treatment in neutropenic fever among hematology patients was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Cancer
• Neutropenia Febrile

Drugs mentioned

• Cefotolozane-tazobactam (cefotolozane-tazobactam)

Snippet

Sponsor: Hamad Medical Corporation | Conditions: Neutropenia, Febrile, Hematologic Cancer | Phase 4 | Status: WITHDRAWN